Enovis Corporation: Arvis Is Disrupting The Health Care Industry

Given Mahlangu 394 Followers Follow Summary Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Arvis, a zero-footprint, wearable augmented reality device for orthopedic surgery, targets the fast-growing ambulatory surgery center market and recently achieved full commercialization. ENOV's fundamentals are weak—slim margins, high leverage, and thin free cash flow—but these are already priced in, while Arvis's growth potential is not. This speculative bet offers roughly 100% upside if Arvis gains traction, but execution, adoption, and funding risks remain material. EvgeniyShkolenko/iStock via Getty Images Investment Thesis Health care is one of the most heavily funded markets in the world, both by corporations and the government. While still heavily funded, the industry suffers from lacking adequate facilities, equipment, and labor to service the insane demand This article was written by Given Mahlangu 394 Followers Follow Full-time Equity Analyst and part-time retail investor with a bias for high quality stocks trading at discounted prices. over the past 5 years I've been retail investing and learning more about how the stock market works, following the work of Ben Graham and Joel Greenblatt. Equity Markets are fascinating as they give us an analytical overview of how global markets are performing. Seeking Alpha is an incredible platform for me to share my research and analysis with fellow investors and analysts. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.